Cargando…
Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma
Neuroendocrine neoplasms (NENs), which are characterized by neuroendocrine differentiation, can arise in various organs. NENs have been divided into well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs) based on morphological differentiation, eac...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10584733/ https://www.ncbi.nlm.nih.gov/pubmed/37422534 http://dx.doi.org/10.1007/s10555-023-10121-2 |
_version_ | 1785122806018605056 |
---|---|
author | Ooki, Akira Osumi, Hiroki Fukuda, Koshiro Yamaguchi, Kensei |
author_facet | Ooki, Akira Osumi, Hiroki Fukuda, Koshiro Yamaguchi, Kensei |
author_sort | Ooki, Akira |
collection | PubMed |
description | Neuroendocrine neoplasms (NENs), which are characterized by neuroendocrine differentiation, can arise in various organs. NENs have been divided into well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs) based on morphological differentiation, each of which has a distinct etiology, molecular profile, and clinicopathological features. While the majority of NECs originate in the pulmonary organs, extrapulmonary NECs occur most predominantly in the gastro-entero-pancreatic (GEP) system. Although platinum-based chemotherapy is the main therapeutic option for recurrent or metastatic GEP-NEC patients, the clinical benefits are limited and associated with a poor prognosis, indicating the clinically urgent need for effective therapeutic agents. The clinical development of molecular-targeted therapies has been hampered due to the rarity of GEP-NECs and the paucity of knowledge on their biology. In this review, we summarize the biology, current treatments, and molecular profiles of GEP-NECs based on the findings of pivotal comprehensive molecular analyses; we also highlight potent therapeutic targets for future precision medicine based on the most recent results of clinical trials. |
format | Online Article Text |
id | pubmed-10584733 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-105847332023-10-20 Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma Ooki, Akira Osumi, Hiroki Fukuda, Koshiro Yamaguchi, Kensei Cancer Metastasis Rev Review Neuroendocrine neoplasms (NENs), which are characterized by neuroendocrine differentiation, can arise in various organs. NENs have been divided into well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs) based on morphological differentiation, each of which has a distinct etiology, molecular profile, and clinicopathological features. While the majority of NECs originate in the pulmonary organs, extrapulmonary NECs occur most predominantly in the gastro-entero-pancreatic (GEP) system. Although platinum-based chemotherapy is the main therapeutic option for recurrent or metastatic GEP-NEC patients, the clinical benefits are limited and associated with a poor prognosis, indicating the clinically urgent need for effective therapeutic agents. The clinical development of molecular-targeted therapies has been hampered due to the rarity of GEP-NECs and the paucity of knowledge on their biology. In this review, we summarize the biology, current treatments, and molecular profiles of GEP-NECs based on the findings of pivotal comprehensive molecular analyses; we also highlight potent therapeutic targets for future precision medicine based on the most recent results of clinical trials. Springer US 2023-07-08 2023 /pmc/articles/PMC10584733/ /pubmed/37422534 http://dx.doi.org/10.1007/s10555-023-10121-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Ooki, Akira Osumi, Hiroki Fukuda, Koshiro Yamaguchi, Kensei Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma |
title | Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma |
title_full | Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma |
title_fullStr | Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma |
title_full_unstemmed | Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma |
title_short | Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma |
title_sort | potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10584733/ https://www.ncbi.nlm.nih.gov/pubmed/37422534 http://dx.doi.org/10.1007/s10555-023-10121-2 |
work_keys_str_mv | AT ookiakira potentmoleculartargetedtherapiesforgastroenteropancreaticneuroendocrinecarcinoma AT osumihiroki potentmoleculartargetedtherapiesforgastroenteropancreaticneuroendocrinecarcinoma AT fukudakoshiro potentmoleculartargetedtherapiesforgastroenteropancreaticneuroendocrinecarcinoma AT yamaguchikensei potentmoleculartargetedtherapiesforgastroenteropancreaticneuroendocrinecarcinoma |